KINSHASA, the Congolese Ministry of Health, says two of the first ten people receiving experimental treatment for the Ebola virus at the recent outbreak have recovered and may be monitoring the role of the treatment  The World Health Organization on Saturday congratulated the Congolese government on providing several experimental treatments for this Ebola outbreak, calling it "a world premiere and a glimmer of hope for those with this disease."
The two patients received treatment mAb114 isolated a survivor of an Ebola outbreak in 1995. It was the first of five experimental treatments the Congo had allowed for the outbreak on 1 August. The others are ZMapp, Remdesivir, Favipiravir and Regn3450 ̵
The WHO Ebola boss on Friday said Ebola has spread to a high-security area, a "crucial" moment affecting the health of the medical community Teams endangered. Several armed groups roam the densely populated northeast of the Congo, and health officials have called "red zones" where attacks pose a serious challenge to finding and monitoring the contacts of infected people.
According to the Congo, 79 Ebola cases were confirmed, including 42 deaths and 14 recovering people. There are another 28 probable cases where biological samples are not available for laboratory testing.
More than 3,400 people have received an experimental Ebola vaccine in this outbreak
Ebola, a hemorrhagic fever, is spread from the infected, including the dead, through contact with body fluids. Depending on the burden, it can be fatal in up to 90 percent of cases. This is the tenth outbreak of the virus in Congo and the first in North Kivu province, which, in addition to the resident population, is home to an estimated 1 million people displaced by fighting.
The affected region in this eruption, which includes the province of Ituri in the north, borders Uganda, Rwanda and southern Sudan. While the WHO says that the risk to public health is high at national and regional levels, it advises against travel restrictions
Copyright © 2018 The Washington Times, LLC.